SCHEMBL885079

SCHEMBL885079

c1cnc(Nc2ccccc2CC(c2cccnc2)c2cccnc2)nc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 13/20 0.56
KCNH2 Q12809 5/20 0.56
CFTR P13569 2/20 0.42
GOPC Q9HD26 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884625 0.86 KCNA5 (0.53) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884862 0.84 KCNA5 (0.57) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884872 0.84 KCNA5 (0.53) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884337 0.83 KCNA5 (0.60) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL2063519 0.80 HPGD (0.48) KCNA5KCNH2SMN1; SMN2CYP1A2CYP3A4
SCHEMBL884575 0.80 KCNA5 (0.52) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884632 0.80 KCNA5 (0.49) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL2062493 0.78 KCNA5 (0.50) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884875 0.78 KCNA5 (0.56) KCNA5KCNH2CFTRGOPCSLC6A2
SCHEMBL884331 0.77 KCNA5 (0.49) KCNA5KCNH2CFTRGOPCSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885CFTR 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.